Progress of autologous hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory large B-cell lymphoma

VernacularTitle:自体造血干细胞移植及嵌合抗原受体T细胞治疗复发难治大B细胞淋巴瘤研究进展
Author: Wenrong HUANG ¹
Author Information

1. 解放军总医院第五医学中心血液病医学部淋巴瘤-浆细胞疾病科，北京　100071
Keywords: Lymphoma, large B-cell; Chimeric antigen receptor T-cell; Autologous hematopoietic stem cell transplantation
From: Journal of Leukemia & Lymphoma 2022;31(2):65-67
CountryChina
Language:Chinese
Abstract: Large B-cell lymphoma (LBCL) is the most common lymphoma subtype in China. Although the application of immuno-chemotherapy has significantly improved the cure rate, 40%-50% of patients will still experience refractory or relapse. Conventional salvage chemotherapy followed by autologous hematopoietic stem-cell transplantation (AHCT) can cure about 40% of chemotherapy-sensitive relapsed/refractory LBCL patients, but about 50% of relapsed/refractory LBCL patients cannot undergo AHCT because of resistance to salvage immunotherapy. Chimeric antigen receptor T-cell (CAR-T) immunotherapy has attracted much attention, and two CD19 CAR-T products have been approved in China for the treatment of relapsed/refractory LBCL. At the 63rd American Society of Hematology Annual Meeting, several international phase 3 trials reported the latest progress of CAR-T and AHCT in the treatment of relapsed/refractory LBCL.